非小细胞肺癌免疫治疗获益人群筛选的研究进展

doi:10.3969/j.issn.1674-8115.2021.08.020

摘要/Abstract

摘要：

免疫检查点抑制剂（immune checkpoint inhibitors，ICIs）投入临床应用后，非小细胞肺癌（non-small cell lung cancer，NSCLC）的治疗步入了全新的时代。但并非所有NSCLC患者都能获益，因此选择合适的生物标志物来预测患者对ICIs的应答水平尤为重要。ICIs作用机制复杂，很多肿瘤免疫反应中涉及的环节（肿瘤相关细胞、分子或基因特征）都可能影响患者对ICIs的应答，因此可用于预测NSCLC患者对ICIs的应答水平。目前已有很多研究在探索现有生物标志物的临床意义与其局限性，并努力发掘潜在的新兴生物标志物，以及联合多重标志物，以期建立更可靠的疗效预测模型。该文基于最新的研究做一综述，归纳目前NSCLC免疫治疗获益人群筛选的生物标志物应用情况与研究进展。

关键词: 非小细胞肺癌, 免疫治疗, 免疫检查点抑制剂, 生物标志物

Abstract:

The application of immune checkpoint inhibitors (ICIs) has brought the treatment of non-small cell lung cancer (NSCLC) into a brand-new age. However, not all patients with NSCLC can benefit from ICIs, and there is currently no good standard for screening the beneficiaries, which provides difficulties for ICIs to bring greater benefits to patients. Therefore, it is quite important to explore suitable biomarkers that can predict the level of patients′ response to ICIs. Due to the complexity of the mechanism of the action of ICIs, many links involved in the tumor immune response, including tumor-related cells, molecules or genetic characteristics, may affect the patients' response to ICIs, and may also have the ability to predict the level of NSCLC patients' response to ICIs at the same time. Currently many studies are exploring the clinical significance and limitations of existing biomarkers, struggling to explore potential emerging biomarkers and combine multiple biomarkers for a more reliable predicting model, in order to bring precise treatment to patients with NSCLC. This article is a review based on the latest research results. It summarizes the current application and research progress of biomarkers to screen NSCLC candidates who will benefit from immunotherapy.

Key words: non-small-cell lung cancer (NSCLC), immunotherapy, immune checkpoint inhibitor (ICI), biomarker

中图分类号:

R734.2

凌徐心仪, 张瑶, 钟华. 非小细胞肺癌免疫治疗获益人群筛选的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(8): 1114-1119.

Xu-xin-yi LING, Yao ZHANG, Hua ZHONG. Research progress in screening non-small cell lung cancer patients who will benefit from immunotherapy[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1114-1119.

参考文献 44

1	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
2	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
3	Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2004, 2(2): 94.
4	Ettinger DS, Wood DE, Aggarwal C, et al. NCCN guidelines insights: non-small cell lung cancer, version 1.2020[J]. J Natl Compr Canc Netw, 2019, 17(12): 1464-1472.
5	Brody R, Zhang Y, Ballas M, et al. PD-L1 expression in advanced NSCLC: insights into risk stratification and treatment selection from a systematic literature review[J]. Lung Cancer, 2017, 112: 200-215.
6	Fehrenbacher L, von Pawel J, Park K, et al. Updated efficacy analysis including secondary population results for OAK: a randomized phase Ⅲ study of atezolizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer[J]. J Thorac Oncol, 2018, 13(8): 1156-1170.
7	Paz-Ares L, Spira A, Raben D, et al. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage Ⅲ non-small-cell lung cancer in the PACIFIC trial[J]. Ann Oncol, 2020, 31(6): 798-806.
8	Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(2): 123-135.
9	Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639.
10	Mazzaschi G, Madeddu D, Falco A, et al. Low PD-1 expression in cytotoxic CD8⁺ tumor-infiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value[J]. Clin Cancer Res, 2018, 24(2): 407-419.
11	Thommen DS, Koelzer VH, Herzig P, et al. A transcriptionally and functionally distinct PD-1⁺ CD8⁺ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade[J]. Nat Med, 2018, 24(7): 994-1004.
12	Gennen K, Käsmann L, Taugner J, et al. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy[J]. Radiat Oncol, 2020, 15(1): 5.
13	Tokito T, Azuma K, Kawahara A, et al. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage Ⅲ non-small cell lung cancer patients receiving concurrent chemoradiotherapy[J]. Eur J Cancer, 2016, 55: 7-14.
14	Lin ZY, Gu JC, Cui XX, et al. Deciphering microenvironment of NSCLC based on CD8+ TIL density and PD-1/PD-L1 expression[J]. J Cancer, 2019, 10(1): 211-222.
15	Mazzaschi G, Facchinetti F, Missale G, et al. The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC[J]. Lung Cancer, 2019, 127: 153-163.
16	Cho YH, Choi MG, Kim DH, et al. Natural killer cells as a potential biomarker for predicting immunotherapy efficacy in patients with non-small cell lung cancer[J]. Target Oncol, 2020, 15(2): 241-247.
17	Bianco A, Perrotta F, Barra G, et al. Prognostic factors and biomarkers of responses to immune checkpoint inhibitors in lung cancer[J]. Int J Mol Sci, 2019, 20(19): E4931.
18	Syed Khaja AS, Toor SM, El Salhat H, et al. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment[J]. Oncotarget, 2017, 8(20): 33159-33171.
19	Syed Khaja AS, Toor SM, El Salhat H, et al. Intratumoral FoxP3⁺Helios⁺ regulatory T cells upregulating immunosuppressive molecules are expanded in human colorectal cancer[J]. Front Immunol, 2017, 8: 619.
20	Wu SP, Liao RQ, Tu HY, et al. Stromal PD-L1-positive regulatory T cells and PD-1-positive CD8-positive T cells define the response of different subsets of non-small cell lung cancer to PD-1/PD-L1 blockade immunotherapy[J]. J Thorac Oncol, 2018, 13(4): 521-532.
21	Weber R, Fleming V, Hu XY, et al. Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors[J]. Front Immunol, 2018, 9: 1310.
22	Prendergast GC, Smith C, Thomas S, et al. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer[J]. Cancer Immunol Immunother, 2014, 63(7): 721-735.
23	Brochez L, Chevolet I, Kruse V. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy[J]. Eur J Cancer, 2017, 76: 167-182.
24	Liu M, Wang X, Wang L, et al. Targeting the IDO1 pathway in cancer: from bench to bedside[J]. J Hematol Oncol, 2018, 11(1): 100.
25	Botticelli A, Cerbelli B, Lionetto L, et al. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?[J]. J Transl Med, 2018, 16(1): 219.
26	Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015, 348(6230): 124-128.
27	Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J]. N Engl J Med, 2018, 378(22): 2093-2104.
28	Wu YF, Xu JM, Du CL, et al. The predictive value of tumor mutation burden on efficacy of immune checkpoint inhibitors in cancers: a systematic review and meta-analysis[J]. Front Oncol, 2019, 9: 1161.
29	McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade[J]. Science, 2016, 351(6280): 1463-1469.
30	Oya Y, Kuroda H, Nakada T, et al. Efficacy of immune checkpoint inhibitor monotherapy for advanced non-small-cell lung cancer with ALK rearrangement[J]. Int J Mol Sci, 2020, 21(7): E2623.
31	Gainor JF, Shaw AT, Sequist LV, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis[J]. Clin Cancer Res, 2016, 22(18): 4585-4593.
32	Dong ZY, Zhang JT, Liu SY, et al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer[J]. Oncoimmunology, 2017, 6(11): e1356145.
33	Kim JH, Kim HS, Kim BJ. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: a meta-analysis and review[J]. Oncotarget, 2017, 8(29): 48248-48252.
34	Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma[J]. Cancer Discov, 2018, 8(7): 822-835.
35	Kauffmann-Guerrero D, Tufman A, Kahnert K, et al. Response to checkpoint inhibition in non-small cell lung cancer with molecular driver alterations[J]. Oncol Res Treat, 2020, 43(6): 289-298.
36	Higgs BW, Morehouse CA, Streicher K, et al. Interferon gamma messenger RNA signature in tumor biopsies predicts outcomes in patients with non-small cell lung carcinoma or urothelial cancer treated with durvalumab[J]. Clin Cancer Res, 2018, 24(16): 3857-3866.
37	Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade[J]. J Clin Invest, 2017, 127(8): 2930-2940.
38	Danaher P, Warren S, Lu RZ, et al. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)[J]. J Immunother Cancer, 2018, 6(1): 63.
39	Mandal R, Chan TA. Personalized oncology meets immunology: the path toward precision immunotherapy[J]. Cancer Discov, 2016, 6(7): 703-713.
40	Dudley JC, Lin MT, Le DT, et al. Microsatellite instability as a biomarker for PD-1 blockade[J]. Clin Cancer Res, 2016, 22(4): 813-820.
41	Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. J Clin Oncol, 2018, 36(8): 773-779.
42	Rizvi H, Sanchez-Vega F, La K, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing[J]. J Clin Oncol, 2018, 36(7): 633-641.
43	Lee JS, Ruppin E. Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1[J]. JAMA Oncol, 2019, 5(11): 1614-1618.
44	Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)[J]. Ann Oncol, 2016, 27(8): 1492-1504.

[1]	熊雷, 易茜, 许明芳, 陈健. MRPL12在肺腺癌中的表达和预后分析[J]. 上海交通大学学报(医学版), 2021, 41(8): 1033-1040.
[2]	李静威, 王俐文, 蒋玲曦, 詹茜, 陈皓, 沈柏用. 胰腺癌免疫抑制性肿瘤微环境研究综述[J]. 上海交通大学学报(医学版), 2021, 41(8): 1103-1108.
[3]	马韵芳, 潘丽娜, 李圳, 高蓓莉, 胡家安, 徐志红. 司美替尼下调KRAS G12V突变型非小细胞肺癌细胞PD-L1水平的探索性研究[J]. 上海交通大学学报(医学版), 2021, 41(6): 741-748.
[4]	唐冬娟，薛晓梅，何斌. miR-133a对急性心肌梗死的早期诊断及预后评估价值[J]. 上海交通大学学报（医学版）, 2020, 40(3): 339-.
[5]	张伟然1, 2，林雪峰3，李鑫2，张浩2，王猛2，孙伟2，韩兴鹏2，孙大强1, 4. 转录组分析鉴定肺腺癌潜在的生物标志物[J]. 上海交通大学学报(医学版), 2020, 40(12): 1598-1606.
[6]	朱琳，刘军. 多系统萎缩生物标志物的研究进展[J]. 上海交通大学学报(医学版), 2020, 40(09): 1302-1307.
[7]	何春明，尹航，郑佳杰，唐健，傅于捷，赵晓菁. 肺癌免疫治疗：免疫抑制细胞和肺内免疫[J]. 上海交通大学学报(医学版), 2020, 40(08): 1137-1142.
[8]	刘洁，仇晓春. 乳腺肿瘤干细胞研究热点及趋势分析[J]. 上海交通大学学报(医学版), 2020, 40(07): 881-888.
[9]	戴飞，魏瑾瑾，汤欣玥，陈峥，蔺林. 舌下含服免疫治疗对效应性T细胞和调节性T细胞功能的影响[J]. 上海交通大学学报(医学版), 2020, 40(05): 626-632.
[10]	王晓霞1，许天祥2，吕镗烽3，胥武剑3，刘建波1，宋勇3. 急性呼吸窘迫综合征患者香叶基香叶基焦磷酸合成酶的表达及其临床意义[J]. 上海交通大学学报(医学版), 2020, 40(05): 639-645.
[11]	况俊良，郑晓皎，赵爱华，贾伟. 代谢性疾病中胆汁酸水平变化及相关治疗策略[J]. 上海交通大学学报（医学版）, 2019, 39(6): 678-.
[12]	屈国君 1，陆元凤 2，李宇 1. PDGFRα下游新底物 CCT2对肿瘤细胞生长的影响及其机制[J]. 上海交通大学学报（医学版）, 2019, 39(1): 28-.
[13]	陶逸菁 1，夏智丽 1，高程洁 2，高亚洁 1，吴昊 3，万青 1，李永光 1，陆志刚 1，沈成兴 1，潘静薇 1. 急性心肌梗死再血管化成功后预测左心室重构相关生物标志物的分析[J]. 上海交通大学学报（医学版）, 2019, 39(1): 60-.
[14]	曹淑慧，周严，李静文，钟华. DCVAC/LuCa联合化疗治疗晚期非小细胞肺癌安全性的探讨[J]. 上海交通大学学报（医学版）, 2018, 38(8): 923-.
[15]	何亚平 1，楼玮群 2，陈杰灵 2，周箴 3，朱静芬 1，简红 3. 病程12个月及以上非小细胞肺癌患者生活质量评估及影响因素研究[J]. 上海交通大学学报（医学版）, 2018, 38(7): 775-.